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One of the most challenging aspects of evidence-based
decision making is the appraisal of the available evidence
in order to separate the wheat from the chaff. It has
been stated that “not all evidence is created equal”
(Cochrane Consumer Network - Levels of evidence),
and it has been recommended to grade the available
literature by the strength of evidence as determined
by the methods used to minimize bias within a
study design (Cochrane Consumer Network - Levels
of evidence; Bossuyt & Leeflang 2008; Gutmann
2009; Mileman & van den Hout 2009; Reitsma
et al. 2009; Rosenberg & Donald 1995; Suebnukarn
et al. 2010; Sutherland & Matthews 2004; Zwahlen
et al. 2008). A cornerstone of this appraisal process
is the use of hierarchical systems for classifying the
evidence. This hierarchy is known as the Levels of evidence
(Burns et al. 2011).Traditional hierarchical systems of levels of
evidence
One of the earliest reports of a Levels of evidence (LOE)
hierarchical system was published in 1979 by the
Canadian Task Force on the Periodic Health Examin-
ation (Burns et al. 2011; Canadian Task Force on the
Periodic Health 1979). LOE was traditionally defined
as “hierarchical grading systems for classifying study
strength/quality” (Burns et al. 2011; Wright et al.
2003; Sutherland 2001; Oxford Centre for Evidence-
based Medicine – The Oxford 2011; Petrisor et al.
2006). Since the introduction of LOE, several other
organizations have adopted various classification sys-
tems, most of which share a lot in common (Bossuyt
& Leeflang 2008; Gutmann 2009; Mileman & van den* Correspondence: dr.eyalrosen@gmail.com
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1995; Suebnukarn et al. 2010; Sutherland & Matthews
2004; Zwahlen et al. 2008; Burns et al. 2011; Canad-
ian Task Force on the Periodic Health 1979). To-date,
classification systems such as the system presented by
the “Oxford Centre for Evidence-Based Medicine”
(Oxford Centre for Evidence-based Medicine – The Ox-
ford 2011) attempt to provide comprehensive hierarchical
grading for classifying scientific evidence (Bossuyt & Lee-
flang 2008; Gutmann 2009; Mileman & van den Hout
2009; Reitsma et al. 2009; Rosenberg & Donald 1995; Sueb-
nukarn et al. 2010; Sutherland & Matthews 2004; Zwahlen
et al. 2008; Burns et al. 2011; Canadian Task Force on the
Periodic Health 1979; Tsesis et al. 2009).
The traditional hierarchical systems of classifying the
evidence primarily use the study design as the basis for
the grading process (Bossuyt & Leeflang 2008; Gutmann
2009; Mileman & van den Hout 2009; Reitsma et al.
2009; Rosenberg & Donald 1995; Suebnukarn et al.
2010; Sutherland & Matthews 2004; Zwahlen et al. 2008;
Burns et al. 2011; Canadian Task Force on the Periodic
Health 1979; Tsesis et al. 2009). A clinical study may be
experimental (interventional) or observational. In experi-
mental studies, the intervention is under the control of the
investigator, whereas in observational studies, the investiga-
tor observes patients at a point in time (cross-sectional
studies) or over time (longitudinal studies). These observa-
tions are done either by looking forward and gathering
new data (prospective), or by collecting already existing
data (retrospective studies) (Sutherland 2001). As an
example of the levels of evidence, in practically all LOE
classification systems Randomized controlled trials (RCTs)
are considered as a high LOE, as opposed to Case reports
and Case series that are considered as a low LOE (Bossuyt
& Leeflang 2008; Gutmann 2009; Mileman & van den
Hout 2009; Reitsma et al. 2009; Rosenberg & Donald
1995; Suebnukarn et al. 2010; Sutherland & Matthews
2004; Zwahlen et al. 2008; Burns et al. 2011;is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
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Levels of evidence from the clinical decision
making perspective
From the clinical perspective, the study design and the
ensuing LOE classification may not always be the most
important factor to consider while assessing the available
evidence. Occasionally, even a well conducted RCT may
not necessarily generate new knowledge superior to the
knowledge gained from a case series study. Thus an
RCT may be less significant to the clinical decision mak-
ing than a case series study. For example, when a clinician
assesses the benefits and risks of a possible treatment
modality, the use of LOE alone can be misleading.
An historical example is the use of Bisphosphonates
for dental purposes:
Bisphosphonates (BPs) are a class of drugs that inhibit
bone resorption and they are successfully used across a
wide range of medical disciplines for bone diseases
(Molvik & Khan 2015; Costa 2014; Anagha & Sen 2014;
Giusti 2014; Bhatt et al. 2014; Eriksen et al. 2014). How-
ever, like any drug, BPs possess the risk of side effects.
BPs-related osteonecrosis of the jaw (BRONJ) has been
characterized as a major side effect of BPs therapy. This
serious side effect may appear following a triggering
event such as tooth extraction (Fliefel et al. 2015). The
earliest descriptions of BRONJ were published in 2003
(Fliefel et al. 2015), including a letter to the editor by
Marx (Marx 2003) who identified 36 cases of painful
jaw bone exposures that were unresponsive to surgical
or medical treatments. All patients were receiving BPs
therapy. Marx stated that: “it represents a heretofore
unrecognized and unreported serious adverse affect;
caution should be used when prescribing these drugs”
(Marx 2003).
This early warning of a potential serious side effect of
BPs and other reports that emerged in the following
months (Ruggiero et al. 2004) had to ring warning bells
(European-Environment-Agency 2001; Kheifets et al.
2001). However, in the following years, placebo-
controlled RCTs that randomized patients to receive BPs
therapies or placebo for periodontal treatment proposes
(Lane et al. 2005), (Rocha et al. 2004), resulted in a
conclusion that “bisphosphonate treatment may be an
appropriate adjunctive treatment to preserve periodon-
tal bone mass” (Lane et al. 2005).
Since then, numerous reports on the development of
BRONJ in patients treated with BPs have been published
(Fliefel et al. 2015; Ruggiero et al. 2004; Ruggiero et al.
2014), and it was realized that the risk for BRONJ after
some periodontal procedures may be comparable to the
risk associated with tooth extraction (Ruggiero et al.
2014). Therefore, in retrospect, the administration ofBPs for periodontal purposes while exposing the patients
to the risk of BRONJ is unthinkable.
At the same time period in which the first reports on
BRONJ emerged in case series of relatively low LOE
(Marx 2003; Ruggiero et al. 2004), other high LOE studies
(RCTs) recommend the use of BPs for dental purposes
(Lane et al. 2005; Rocha et al. 2004; Rocha et al. 2001;
Tenenbaum et al. 2002). This fact highlights the conclu-
sion that high LOE studies don’t always contribute new
knowledge to support the practitioner’s clinical decision
making that is superior to new knowledge from low LOE
studies, and that the study design alone as a decisive factor
for the evidence appraisal, can be misleading.A comprehensive approach for assessing evidence
as the basis for clinical decision making
Traditional study-design-based LOE grading systems
may therefore only provide information on the credibility
of the study’s results, but do not provide any information
regarding the relevance of the investigated clinical question
to the practitioner’s decision making. Thus, not only the
strength of the evidence should be considered but also the
clinical significance and relevance of the evidence, i.e. how
appropriate the outcome measure is for assessing the bene-
fits (or harms) of the treatment (Cochrane Consumer
Network - Levels of evidence) in the relevant patients.
In addition, these traditional hierarchal systems of
classifying evidence, with RCTs at their top end, were
developed to a large extent for questions related to inter-
ventional studies. For questions related to diagnosis,
prognosis or causation, other study designs such as co-
hort studies may often be more appropriate, and for
these types of studies, it is useful to think of the various
study designs not as a hierarchy, but as categories of evi-
dence, where the strongest design which is possible,
practical and ethical should be used (Sutherland 2001).
Therefore, different types of questions require different
types of evidence (Richards 2009).
Thus, classifying the evidence should not be done by
using the traditional hierarchical systems of LOE alone
(Richards 2009). A comprehensive appraisal of the evi-
dence regarding a specific clinical question should com-
bine an assessment of the strength of the evidence with
other dimensions such as the significance and relevance
of the evidence (Sutherland 2001).The significance and relevance of the evidence
Unlike the well-established hierarchical systems of clas-
sifying the strength of evidence (Cochrane Consumer
Network - Levels of evidence); Burns et al. 2011;
Sutherland 2001; Oxford Centre for Evidence-based
Medicine – The Oxford 2011; Petrisor et al. 2006;
Richards 2009), to-date, determining the significance
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Clinical significance may be defined as “the practical or
applied value or importance of the effect of an interven-
tion” (Kazdin 1999). Treatments that produce reliable
effects may be quite different in their impact on patients’
function, and clinical significance brings this issue to light
(Kazdin 1999). The assessment of clinical significance rep-
resents an important advancement in the evaluation of
effects of interventions, including treatments, but also
extending to prevention, education, and rehabilitation
(Kazdin 1999). This assessment of the importance of the
change and the impact on patient function adds critical di-
mensions to the overall evaluation of the evidence.
The relevance of the evidence may be defined as “the
appropriateness of the outcomes measured including any
outcomes that are likely to be important to patients”
(Medical Research Council 2000). It is an important di-
mension of the evidence appraisal that includes the assess-
ment of several aspects regarding the appropriateness of
the outcomes, such as: their potential short and the long-
term effects; their causal relation to outcomes of
importance to the patient; and the extent to which the
intervention can be replicated in other settings and patient
groups unlike those in which its efficacy has been tested
(Medical Research Council 2000).
In conclusion
The goal of decision making in healthcare is to choose
the interventions that are most likely to deliver the
outcomes that are of most interest to patients, and to
prevent possible harmful outcomes. In this context, it is
important to review the information about the strength
of the evidence (LOE), together with the clinical signifi-
cance and relevance of the evidence.
It will be useful for the medical community to develop
hierarchical systems for classifying the significance and
relevance of the evidence to enable a more objective
evaluation process.
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